Revvity, Inc, a global leader in technology solutions, has announced a transformative strategic partnership with Element Biosciences, Inc., a pioneering life sciences company dedicated to democratizing advanced DNA and multi-omic sequencing technologies. Together, they will co-develop and commercialize a cutting-edge in vitro diagnostic (IVD) solution for neonatal sequencing. This collaboration leverages both companies’ strengths, building on Revvity’s recent advancement in automated next-generation sequencing (NGS) workflows for newborn sequencing research and Element’s momentum toward achieving regulatory approval for its AVITI™ benchtop sequencing system.
This agreement will enable the creation of a comprehensive IVD solution specifically designed for newborn sequencing, offering enhanced capabilities for clinical and research environments. As part of the collaboration, customers will gain immediate access to a research-use-only (RUO) version of the neonatal sequencing research workflow, marking a significant milestone in neonatal genomics.
“This partnership is a key step forward in our mission to advance newborn health through innovative genomic technologies,” said Yves Dubaquie, Senior Vice President, Diagnostics at Revvity. “By combining our expertise in newborn screening and rare disease detection with Element’s state-of-the-art sequencing technology, we aim to deliver a robust, efficient, and accessible solution for neonatal sequencing that can be used across both research and clinical settings.”
Also Read: A2 Biotherapeutics Secures $80M in Series C for Precision Cell Therapies
The newly developed IVD solution represents an important and strategic expansion for both companies. The collaboration will broaden the reach of Element’s AVITI sequencing platform and Revvity’s suite of neonatal sequencing research tools, which includes state-of-the-art sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handlers, NGS library preparation kits with specially curated panels, and sophisticated software for variant calling and data analysis. This combination of advanced technologies will provide a complete, end-to-end solution for the NGS workflow, supporting groundbreaking neonatal research and aiding in the regulatory approvals necessary to bring this innovative IVD product to market.
“Our collaboration with Revvity on this IVD solution will deliver a comprehensive, high-quality offering that meets the diverse needs of newborn screening programs globally,” said Yaron Hakak, Senior Vice President of Corporate and Business Development at Element. “Element remains committed to securing regulatory approval for the AVITI system, paving the way for the introduction of transformative diagnostic solutions from Revvity and other industry-leading partners.”
This collaboration highlights the shared vision of both Revvity and Element Biosciences to revolutionize neonatal testing and screening, advancing precision medicine for newborns and fostering better health outcomes through cutting-edge genomic solutions.